Disappointing data lead Pfizer to drop heart drug acquired as part of $11B deal
14 days ago - By MedCity News
Pfizer is stopping work on a drug for a rare heart disease after an interim look at Phase 3 data indicated that the study was unlikely to succeed. The small molecule came to Pfizer's drug pipeline as part of the $11.4 billion acquisition of Array Biopharma in 2019.
Read more ...
The headlines of Care Mag
CDC Warns of ‘Fast-Moving' E. Coli Outbreak-Here's What You Need to Know
It has caused 29 illnesses and nine hospitalizations in Ohio and Michigan.
Should You Be Worried About West Nile Virus Right Now?
Here's what to keep in mind after the two recent cases in New York.
Here's What You Should Do If You Think You Have Monkeypox Symptoms
You may have to advocate for yourself if a doctor doesn't take you seriously.
Sigma Beauty's "Alice in Wonderland" Collection Mixes Magic and Makeup
If you are a Disney fan who just so happens to also be a makeup-lover , then you are in luck. Sigma beauty is releasing an "Alice in Wonderland" collaboration, and it's all but...
Let's Settle The Debate: Is Room Temperature Water Better For You Than Cold?
Grab a glass of water and get reading!
How To Talk Dirty IRL Or While Sexting: Erotica Writers Weigh In
There's something hot about talking dirty with a partner, whether you're sending them a naughty text during the workday or whispering something seductive while doing the deed...
As Aesthetic Tastes Change, Cosmetic Surgery Reversals Are Trending
Botox's ephemeral nature can be either its best or worst quality. We all want it to last longer - until we don't. Until our lip flip prevents us from swishing our morning...
I'm A Cosmetic Chemist & This Tip Will Make Your Lip Balm Work Even Better
Sometimes, it's not the product itself that works wonders but how you apply it.
STAT+: Medicare may eventually negotiate some drug prices, but Colorado...
The Biden administration may have signed a law designed to lower prescription drug prices, but Colorado state officials are pressing ahead with plans to win federal approval to...
'Wild' And 'Chaotic': Inside The Job Of A Nail Polish Creator
Michelle Lin, the founder and CEO of Mooncat, shares everything that goes into the process. It's not for everyone.